[{"orgOrder":0,"company":"Atox Bio","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Reltecimod","moa":"immunomodulators","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atox Bio \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Atox Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Reltecimod","moa":"immunomodulators","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atox Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/ Undisclosed"},{"orgOrder":0,"company":"Atox Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Reltecimod","moa":"immunomodulators","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atox Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Atox Bio \/ Undisclosed"},{"orgOrder":0,"company":"Atox Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Reltecimod","moa":"immunomodulators","graph1":"Nephrology","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atox Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/ Undisclosed"},{"orgOrder":0,"company":"Atox Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Reltecimod","moa":"immunomodulators","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atox Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/ Undisclosed"}]